ClinicalTrials.gg
RecruitingNCT07226804Updated Jun 1, 2026

Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules

An observational study in Thyroid Nodules and Pulsed Field Ablation, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by M.D. Anderson Cancer Center · Observational

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Study summary

To observe the outcomes of nsPFA therapy to treat benign thyroid nodules.

Read the detailed description

Primary Objectives

  • To evaluate the thyroid nodule volume changes over time in participants undergoing nsPFA as part of routine clinical care

Secondary Objectives

  • To determine changes in health-related quality of life changes following ultrasound-guided nsPFA
  • To evaluate the ultrasound features of thyroid nodules over time following ultrasound-guided nsPFA.
  • To assess the incidence and nature of complications following ultrasound-guided nsPFA, categorized into Minor and Major complications.
02

Conditions studied

  • Thyroid Nodules
  • Pulsed Field Ablation

Browse trials for

03

In context

Thyroid Nodule

207 studies on the registry are indexed under Thyroid Nodule; 64 are open to participants now.

This study's planned enrollment of 30 is below the median of 161 across 82 observational studies indexed under Thyroid Nodule.

Browse Thyroid Nodule studies →

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 3,047 studies on the registry; 578 are open to participants now.

Of its 612 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

MD Anderson Cancer Center

Eligibility criteria

Eligibility Criteria

  • Scheduled to undergo ultrasound guided nsPFA as standard of care
  • Age 18 to 80 years.
  • Capable of providing independent consent.
  • Presence of -confirmed benign thyroid nodule , defined as one of the following:

    • Benign FNA X 2 or
    • Benign US guided FNA X 1 + benign thyroid nodule ultrasound appearance (TI-RADS 2) or
    • Benign FNA X 1 and radiographic/laboratory evidence of functional nature
  • Nodule measuring >2cm in greatest dimension
  • Presence of compressive symptoms reasonably attributable to thyroid nodule (i.e. pressure sensation, dysphagia, dysphonia, respiratory distress)
  • No abnormal cervical lymph nodes during screening visit .

Exclusion Criteria

  • Age \<18
  • Patients considered unsuitable for nsPFA by the treating physician
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Interventions

  • OtherQuestionnaire

    patient-reported outcomes questionnaire

06

What researchers measure

Primary outcomes

  1. Quality-of-life Questionnaire

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07226804
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Nov 14, 2025
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2030 (estimated)
Last update
Jun 1, 2026

Study contacts

Victoria E Banuchi, MD
Contact
vebanuchi@mdanderson.org
346-217-8668
Victoria E Banuchi, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion